ONDERO TAB

About

ONDERO TAB contains Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, indicated for the treatment of type 2 diabetes mellitus. Linagliptin works by selectively inhibiting the enzyme DPP-4, which is responsible for the degradation of incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preserving these incretin hormones, Linagliptin enhances glucose-dependent insulin secretion from pancreatic beta cells and reduces glucagon secretion from pancreatic alpha cells. This mechanism helps to lower elevated blood glucose levels both post-meal and fasting, leading to improved glycemic control. Linagliptin is unique among DPP-4 inhibitors as it is primarily excreted unchanged via the enterohepatic system, requiring no dose adjustment for renal impairment, making it a suitable option for a broad range of patients.

Uses

• Management of type 2 diabetes mellitus.
• To improve glycemic control in adults.
• As monotherapy or combination therapy.
• When diet and exercise are insufficient.

Directions For Use

Take orally once daily, with or without food, as directed by your physician. Swallow the tablet whole with water.

Benefits

• Effective blood sugar reduction.
• No dose adjustment needed for renal impairment.
• Low risk of hypoglycemia when used alone.
• Does not cause weight gain.
• Convenient once-daily dosing.
• Improves pancreatic beta-cell function.

Side Effects

• Nasopharyngitis
• Cough
• Diarrhea
• Hypoglycemia (with sulfonylurea/insulin)
• Pancreatitis (rare)
• Joint pain
• Headache
• Upper respiratory tract infection
• Hypersensitivity reactions
• Bullous pemphigoid (rare)
• Constipation
• Back pain

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable. Excessive intake may increase hypoglycemia risk, especially if combined with other antidiabetic drugs.
• Pregnancy - Not recommended during pregnancy. Consult a healthcare professional to weigh potential risks and benefits.
• Breastfeeding - Avoid during breastfeeding as it may pass into breast milk. Seek medical advice.
• Liver - No dose adjustment is required for patients with hepatic impairment.
• Kidney - No dose adjustment is required for patients with renal impairment, including end-stage renal disease.
• Lung - Generally considered safe for use in individuals with pre-existing lung conditions. No specific pulmonary contraindications.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.